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Age-associated changes in the immune system including alterations in surface protein 
expression are thought to contribute to an increased susceptibility for autoimmune 
diseases. The balance between the expression of coinhibitory and costimulatory surface 
protein molecules, also known as immune checkpoint molecules, is crucial in fine-tuning 
the immune response and preventing autoimmunity. The activation of specific inhibitory 
signaling pathways allows cancer cells to evade recognition and destruction by the host 
immune system. The use of immune checkpoint inhibitors (ICIs) to treat cancer has 
proven to be effective producing durable antitumor responses in multiple cancer types. 
However, one of the disadvantages derived from the use of these agents is the appear-
ance of inflammatory manifestations termed immune-related adverse events (irAEs). 
These irAEs are often relatively mild, but more severe irAEs have been reported as well 
including several forms of vasculitis. In this article, we argue that age-related changes in 
expression and function of immune checkpoint molecules lead to an unstable immune 
system, which is prone to tolerance failure and autoimmune vasculitis development. The 
topic is introduced by a case report from our hospital describing a melanoma patient 
treated with ICIs and who subsequently developed biopsy-proven giant cell arteritis. 
Following this case report, we present an in-depth review on the role of immune check-
point pathways in the development and progression of autoimmune vasculitis and its 
relation with an aging immune system.
Keywords: immune checkpoints, immune checkpoint inhibitors, immune-related adverse events, vasculitis, giant 
cell arteritis
iNtrODUctiON
Age-associated changes in the immune system are thought to contribute to an increased susceptibil-
ity for autoimmune diseases. These changes include shifts in immune cell numbers, distribution, 
and function in conjunction with alterations in cell surface protein expression. One important class 
of surface proteins expressed on immune cells is immune checkpoint molecules, which regulate 
T cell activation by relaying positive (costimulatory) and negative (coinhibitory) signals. The balance 
between the expression of coinhibitory and costimulatory molecules is crucial in fine-tuning the 
immune response and preventing autoimmunity.
tABle 1 | Reported cases of vasculitis developed after immune checkpoint 
inhibitor treatment.
reference reported case
van den Brom et al. (7) Granulomatosis with polyangiitis induced by immune 
checkpoint inhibition (α-CTLA-4 and α-PD-1)
Minor et al. (8) Lymphocytic vasculitis of the uterus in a patient with 
melanoma receiving ipilimumab
Goldstein et al. (9) Polymyalgia rheumatica/giant cell arteritis occurring in 
two patients after treatment with ipilimumab
Hodi et al. (10) Giant cell arteritis in a patient with metastatic melanoma 
receiving bevacizumab plus ipilimumab
Calabrese et al. (11) Rheumatic immune-related adverse events of 
checkpoint therapy for cancer (PMR-like syndrome in 
three patients: two receiving α-PD-1 and one receiving 
α-CTLA-4 and α-PD-1)
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By exploiting the activation of specific inhibitory signal-
ing pathways, cancer cells are able to evade recognition and 
destruction by the host immune system. Currently, several 
coinhibitory molecules are targeted by antibody-based 
antagonist biologicals in cancer immunotherapy. The rationale 
for this approach is that blockade of inhibitory checkpoints 
causes an unrestrained immune response allowing the host’s 
tumor-specific T cells to attack the tumor cells. This immune 
checkpoint blockade strategy has proven to be very effective, 
producing long-lasting antitumor responses in multiple cancer 
types (1–3).
Nevertheless, immune checkpoint therapy has its disadvan-
tages. Blocking the inhibitory signaling pathways may unleash 
reactivity to healthy tissues, which consequently may result in 
inflammatory manifestations in patients receiving these agents, 
termed immune-related adverse events (irAEs) (3–6). These 
irAEs are often relatively mild, but more severe irAEs have been 
reported as well including several forms of vasculitis such as 
granulomatosis with polyangiitis (GPA) (7), lymphocytic vascu-
litis (8), and polymyalgia rheumatica/giant cell arteritis (9–11) 
(Table 1).
However, little is known about the role of immune check-
points in vasculitis. In this article, we discuss the evidence that 
age-associated changes in expression and function of immune 
checkpoint molecules leads to an imbalance of the immune 
system. An immune system out of balance is prone to tolerance 
failure and the development of autoimmune vasculitis. The topic 
is introduced by a case report from our hospital describing a 
melanoma patient treated with immune checkpoint inhibitors 
(ICIs) and who subsequently developed biopsy-proven giant cell 
arteritis. This case study sets the stage for a more in-depth review 
on the role of immune checkpoint pathways in the development 
and progression of autoimmune vasculitis and its relation with 
the aging immune system.
cAse viGNette
A 70-year-old man with a history of hepatitis A and who had 
a myocardial infarction in 2001 developed a melanoma of the 
skin of the left temple in 2015. He was diagnosed with stage IIIB 
BRAF mutated melanoma and was treated with modified radical 
dissections including a parotidectomy, a neck dissection, and a 
free skin transplantation on June 8, 2015.
In August 2015, he started with adjuvant treatment in a 
double-blind study CA209-238 (Efficacy Study of Nivolumab 
Compared to Ipilimumab in Prevention of Recurrence of 
Melanoma after Complete Resection of Stage IIIb/c or Stage 
IV Melanoma (CheckMate 238); ClinicalTrials.gov number, 
NCT02388906) until April 2016. In April 2016, he was referred 
to the rheumatology and clinical immunology department 
with the following complaints: fatigue, low-grade fever with 
a temperature reaching 38.5 C, night sweats, and weight loss 
of 4 kg in 2 weeks. He had also experienced continuous pain 
for 4 weeks in his jaws and mastoid muscles. The right temple 
and masseter muscle were painful upon palpation, and his 
pain increased upon chewing. He had no hair pain or visual 
problems. He developed also new-onset pain and stiffness in 
his upper legs, neck, and shoulders. He had no pain or stiff-
ness in his smaller joints, excluding a diagnosis fitting with 
arthritis.
On physical examination, he was fatigued, his blood pressure 
was 140/70 (upon measurement in both arms), his height was 
1.78  m, and his weight 62  kg. His right temporal artery was 
painful, and his left temporal artery was not palpable (status 
after radical surgery). His shoulders and upper legs were painful 
upon movement. He had no infectious, gastrointestinal, or skin 
symptoms. His blood tests showed an elevated ESR of 93 mm/h, 
CRP of 52 mg/L, a hemoglobin level of 7.8 mmol/L (in October 
2015, before immune checkpoint treatment, these values were 
ESR of 37 mm/h, CRP of 1.6 mg/L, and a hemoglobin level of 
8.1 mmol/L).
An ultrasound of the temporal and axillary arteries, a PET/
CT scan, and a temporal artery biopsy were performed. No halo 
fitting with GCA was observed upon US of his temporal and 
axillary arteries and muscles. The PET/CT did not show signs of 
large vessel vasculitis (LVV), myositis, infections, or metastasis, 
but did show some uptake surrounding both hips that would fit 
with a diagnosis of PMR. An additional MRI was performed, 
which did not show cerebral or leptomeningeal metastasis, and 
the masseter and temporal muscle and temporal and facial artery 
on the right side appeared to be normal. The ophthalmologist and 
the neurologist found no signs and symptoms that would fit the 
diagnosis of GCA and also ruled out trigeminal neuralgia.
The complaints of the patient were progressive, and his ESR 
and CRP remained high, while his right temporal artery increased 
in size and remained painful upon palpation. On May 23, 2016, 
the patient underwent a temporal artery biopsy from his right 
temporal artery, which revealed a transmural inflammation of 
the adventitial, medial, and intimal layers of the temporal artery 
with a fragmented internal and external lamina elastic, diagnostic 
for GCA (Figure 1). On May 24, the patient started with high-
dose prednisolone (60 mg/day), which was tapered to 30 mg/day 
on May 25 (due to severe side effects) and gradually tapered to 
2.5 mg/day on November 3, 2016. Disease activity of GCA was 
monitored according to the BSR definition that a disease relapse 
should be suspected in patients with a return of symptoms of 
GCA, ischemic complications, or unexplained constitutional or 
FiGUre 1 | Temporal artery biopsy of the case report patient showing transmural inflammation of the adventitial, medial, and intimal layers with a fragmented 
internal and external lamina elastic (white arrows) (Verhoeff–Van Gieson staining).
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polymyalgic symptoms. (Relapse is usually associated with an 
increase in erythrocyte sedimentation rate/C-reactive protein, 
but may occur with normal inflammatory markers.)
Unfortunately, in October 2016, he had developed metastasized 
melanoma (lymph nodes and lung), and his previous adjuvant 
treatment was deblinded (not allowed to mention in this article 
nivolumab or ipilimumab as the study is not yet deblinded). On 
November 3, he started with a different checkpoint inhibitor. He 
had some persistent smoldering low-grade GCA complaints, 
which increased on this treatment. The complaints consisted of 
a headache on his left side and pain and stiffness in his neck and 
upper legs, and he had a painful temporal artery on his left side. 
The ESR of 37 mm/h and CRP of 7 mg/dL were slightly increased, 
suggesting a GCA relapse. The prednisolone dose was increased 
to 10 mg/day. Infusions with checkpoint inhibition were contin-
ued, and he was advised to take an increased prednisolone dose 
of 20 mg at day 2 and 3 after these infusions.
In May 2017, he still had signs and symptoms that fit with 
active GCA, especially jaw complaints upon chewing but no 
headache. The ESR was 4 mm/h and CRP was <0.3 mg/dL. He 
was advised to taper the prednisone to 7.5 mg/day to control the 
GCA without giving too much immunosuppression. A schematic 
representation of GCA development induced by immune check-
point blockade is given in Figure 2.
The case described above is a prime example of an adverse 
consequence upon immune checkpoint therapy, illustrating that 
removing the natural brakes of the immune system may lead to 
a breach of tolerance and development of autoimmunity, such 
as LVV in this example (Figure 3). In this case, the patient was 
treated with in total two ICIs. ICIs are FDA-approved drugs in 
the treatment of advanced melanoma. Ipilimumab was the first 
checkpoint inhibitor approved by the FDA in 2011 for the treat-
ment of advanced melanoma (12), and it showed improved effi-
cacy and survival benefits compared to other chemotherapeutic 
agents (13). PD-1 inhibition with pembrolizumab and nivolumab 
also has proven to be effective in advanced melanoma (14–17) 
and was approved by the FDA in 2014.
Besides anti-PD-1 agents, the FDA has also recently approved 
antiprogrammed death-ligand 1 (PD-L1) agents for the treatment 
of patients with several types of cancer (18, 19). In the coming 
years, the approval of new ICIs or a combination of checkpoint-
targeting agents that are currently under investigation in 
oncology clinical trials is expected. Approval of these drugs will 
translate into an increased use of immunotherapies, prompting 
the investigation of the underlying mechanisms of immune 
checkpoint regulation to avoid unwanted adverse events such as 
the one presented in the case above.
Although there is an increased awareness of the more common 
irAEs upon immune checkpoint therapies, rare but severe and 
potentially life-threatening autoimmune manifestations, such 
as vasculitis, should be taken into account when evaluating the 
benefit of tumor destruction and the associated risks of immu-
notoxicity. Some of the toxicities related to immune checkpoint 
therapy reported in multiple studies are summarized in Table 2 
(16, 20, 21). The reported rate for the more common irAEs, which 
involve the skin, gastrointestinal system, and endocrine system 
FiGUre 3 | Schematic model of the pathogenesis of giant cell arteritis, facilitated by the state of chronic inflammation in aged individuals and in addition by an 
overactivated immune system triggered by immune checkpoint inhibitor treatment. The inflammatory response in the arterial wall is initiated when resident dendritic 
cells (DCs) sense danger signals via pattern recognition receptors such as toll-like receptors. Activated DCs produce chemokines (CCL18, CCL19, CCL20, and 
CCL21), which recruit CD4+ T cells; once recruited in the arterial wall, CD4+ T cells are activated by DCs presenting still undefined antigen(s). The presence of 
pro-inflammatory cytokines (IL-6, IL-1β, IL-23, IL-18, and IL-12) in the microenvironment polarizes CD4+ T cells toward Th1 and Th17 cells, which produce large 
amounts of IFN-γ and IL-17. Eventually, monocytes enter the vascular wall and differentiate into macrophages promoting vascular inflammation by secreting 
cytokines and vascular damage via secretion of matrix metalloproteinases (MMPs). Macrophages, giant cells or injured VSMC also produce growth factors such as 
platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF). This results in vascular remodeling: intimal hyperplasia and vessel occlusion. 
The whole process is facilitated by a state of chronic inflammation as observed in aged individuals and additionally by an overactivated immune system triggered  
by immune checkpoint therapy treatment in this case.
FiGUre 2 | Timeline of events leading to the development of GCA induced by checkpoint immunotherapy. CRP, C-reactive protein; ESR, erythrocyte sedimentation 
rate; GC, glucocorticoids; GCA, giant cell arteritis; ICI, immune checkpoint inhibitor. Surgery included a modified radical dissections including a parotidectomy, a 
neck dissection, and a free skin transplantation on June 8, 2015, for stage IIIb melanoma, which was followed by inclusion in the CA209-238 study [Efficacy Study 
of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238); 
ClinicalTrials.gov number, NCT02388906].
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tABle 2 | Frequency of selected immune-related adverse events associated 
with immune checkpoint inhibitor treatment.a








Robert et al. (16)b 14.5 14.7 NR
Postow et al. (20, 37)c 26 NR 41
Larkin et al. (21)d 32.8 25.9 40.3
Range 15–33% 15–26% 40–41%
Gastrointestinal (diarrhea)
Robert et al. (16)b 22.7 16.9 NR
Postow et al. (20, 37)c 37 NR 45
Larkin et al. (21)d 33.1 19.2 44.1
Range 23–37% 17–19% 44–45%
endocrine (hypothyroidism)
Robert et al. (16)b 2 10.1 NR
Postow et al. (20, 37)c 15 NR 16
Larkin et al. (21)d 4.2 8.6 15
Range 2–15% 9–10% 15–16%
Others (arthralgia)
Robert et al. (16)b 5.1 9.4 NR
Postow et al. (20, 37)c 9 NR 11
Larkin et al. (21)d 6.1 7.7 10.5
Range 5–9% 8–9% 10–11%
aValues are the percentage of treated patients who experienced adverse events of any 
grade (based on the common terminology criteria for adverse events grading system).
bIpilimumab (N = 256), anti-PD-1 agent used: pembrolizumab (N = 278).
cIpilimumab (N = 46); combination therapy used: nivolumab plus ipilimumab (N = 94).
dIpilimumab (N = 311); anti-PD-1 agent used: nivolumab (N = 313); combination 
therapy used: nivolumab plus ipilimumab (N = 313).
NR, not reported.
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are comparable when using only one ICI, but the reported rate for 
these irAEs significantly increases when a combination of thera-
pies is used. For those types of disorders that are not as common, 
the reporting rate is very low, even when combination therapy 
is used. The frequency of autoimmune complications may be 
underestimated due to the fact that follow-up in clinical trials is 
usually short, and the development of autoimmune toxicities can 
have a delayed onset (22).
To better understand the mechanisms of action of ICIs and 
the adverse consequences derived from their use, it is essential 
to consider the various immune functions that these checkpoints 
control; this issue is addressed in the following sections.
cOiNHiBitOrY cHecKPOiNt PAtHWAYs
The two inhibitory checkpoint pathways that have been most 
widely studied in oncology are the CTLA-4 and PD-1 pathways. 
Immune responses are negatively regulated by these pathways at 
different levels and by different mechanisms.
ctlA-4 Pathway
The ability of the immune system to protect from harm and pre-
vent unnecessary tissue injury is maintained by a delicate balance 
between costimulatory and coinhibitory molecules. One example 
of this delicate balance is the interaction between the coinhibi-
tory molecule CTLA-4 and its counterpart, the costimulatory 
molecule CD28. Both CD28 and CTLA-4 are expressed on 
T cells and control the early stages of T cell activation (23–25). 
Once antigen recognition occurs through engagement of the 
T cell receptor (TCR) with the cognate antigen–MHC complex, 
presented by antigen-presenting cells (APCs), CD28 binds to 
CD80 and CD86; this binding strongly amplifies TCR signaling 
to activate T cells (25–28). Within 48 h of activation, expression 
of CTLA-4 is upregulated on activated T cells (3). As CD28 and 
CTLA-4 share identical ligands, the latter dampens T cell activa-
tion by outcompeting the former in binding to CD80 and CD86 
(24, 29–31). CTLA-4 can further decrease activation by sending 
a signal to APCs to reduce CD80/86 expression (32) and secrete 
indoleamine 2,3-dioxygenase (IDO), an enzyme that catalyzes 
tryptophan degradation (33), disabling T lymphocytes to prolif-
erate due to tryptophan shortage (34). Activated CD8+ T cells 
also express CTLA-4, which suppresses helper T cell activity and 
enhances the immunosuppressive activity of regulatory T (Treg) 
cells (35). Treg cells constitutively express CTLA-4, which on the 
one hand leads to Treg cell proliferation and enhanced produc-
tion of IL-35, IL-10, TGF-β, and IDO. On the other hand, on 
effector T (Teff) cells, CTLA-4 engagement causes a decreased 
activation and proliferation (6, 36).
Collectively, as CTLA-4 regulation takes place early in the 
process of T cell activation and augments Treg function, it is likely 
that its blockade leads to an unrestrained non-specific activation 
of the immune response. This broad activation may explain the 
wide variety of adverse events seen when this pathway is blocked 
(25, 37).
PD-1 Pathway
Although both CTLA-4 and PD-1 are negative checkpoints, 
PD-1 exerts its function at different levels and via different 
mechanisms. Upon engagement to either PD-L1 (also known 
as CD274 and B7-H1) or programmed death-ligand 2 (PD-L2; 
also known as CD273 and B7-DC), tyrosine phosphorylation of 
the PD-1 cytoplasmic domain occurs and tyrosine phosphatase 
SHP-2 is recruited, resulting in disruption of the TCR signaling 
cascade (38–41). These effects ultimately block T cell prolifera-
tion, diminish cytokine production and cytolytic function, and 
impair T cell survival (3, 42, 43). The cellular expression of PD-1 
is broader than that of CTLA-4; for example, B cells and natural 
killer cells also express and upregulate PD-1 upon activation (25, 
44), thereby temporarily dampening their effector functions (39). 
Another important subset of T cells that highly expresses PD-1 
is Treg cells, and it has been demonstrated that PD-1 ligation on 
these cells enhances their immunosuppressive activity (43, 45). 
Both the PD-L1 and PD-L2 ligands are expressed on APCs and 
other hematopoietic and non-hematopoietic cell types (46).
In preclinical models, PD-1/PD-L1 pathway inhibition also 
generates antitumor activity and enhances autoimmunity (47). 
However, the autoimmune phenotypes of mice with PD-1 or 
CTLA-4 deficiencies are different. CTLA-4 deficiency results in 
a more severe, non-specific autoimmune phenotype as it affects 
both cell-intrinsic activities (on Teff cells) and cell-extrinsic 
activities (on Treg cells) (48). By contrast, PD-1 deficiency results 
in a mild and chronic autoimmune phenotype since it is mainly 
manifested as cell-intrinsic alterations of Teff cells (3, 48). Since 
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PD-1 activation suppresses the immune response during the 
effector phase of T  cell activation and upon repeated antigen 
exposure, PD-1 blockade probably targets a more restricted 
assortment of T cells than CTLA-4 blockade (3).
lessONs leArNeD FrOM ONcOlOGY
The cancer immunity cycle described by Chen and Mellman 
in 2013 has become a useful framework for immunotherapy 
research. Briefly, the authors refer to seven steps, which need to 
be initiated and allowed to proceed and expand iteratively for an 
anticancer immune response to effectively kill cancer cells. These 
steps involve: step 1: the release of cancer antigens, step 2: presen-
tation of those antigens through APCs and dendritic cells (DCs), 
step 3: T cell priming and activation within the lymph node, step 
4: T cell trafficking to tumors, step 5: T cell infiltration into the 
tumor, step 6: recognition of cancer cells by T cells, and finally, 
step 7: cancer cell killing, which restarts the cycle (49). In each 
step described above, as in all of the immune system processes, 
checks and balances are required to perform optimally, which in 
cancer patients are ablated due to cancer’s many strategies to evade 
recognition by the host immune system. Obstacles encountered 
in one or several steps of the cancer-immunity cycle are the target 
of immunotherapy; therefore, combination of approaches with 
therapies stimulating various and different steps of the cycle may 
result in higher response rates (50) and consequently more irAEs.
effect of immunotherapies on checkpoint 
Molecule expression and Function
In cancer patients, anti-CTLA-4 treatment lowers the threshold 
required for T cell activation, which leads to an expansion of cir-
culating low-avidity T cells (51), resulting in a sustained immune 
response. In addition, it has been shown that anti-CTLA-4 therapy 
promotes antitumor activity by a selective reduction of intratu-
moral Treg via Fc-γR-mediated depletion (52), impairing Treg 
cell survival and function along with concomitant activation of 
Teff cells (35, 53). In addition, Th17 cells, which are implicated in 
many autoimmune and chronic inflammatory disorders (54) and 
in tumor eradication (55) processes, are also affected by CTLA-4 
blocking. In cancer patients, it has been demonstrated that upon 
anti-CTLA-4 treatment, the number of circulating Th17 cells in 
patients increases, especially in those patients who developed 
clinically relevant inflammatory and autoimmune toxicities (56).
Recently, Wei et  al. confirmed that distinct cellular mecha-
nisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. 
The authors concluded that both checkpoint blockade therapies 
targeted only specific tumor-infiltrating exhausted-like CD8 
T  cells and that the effect of these agents primarily differed in 
the expansion of inducible costimulator (ICOS)  +  Th1-like 
CD4 effector cells induced by the anti-CTLA-4 agent (57). 
Furthermore, additional studies in cancer patients show that after 
targeting CTLA-4 with ipilimumab, responding patients have 
increased ICOS + T cells (58, 59). Several research groups have 
reported that there appears to be a compensatory upregulation of 
alternative checkpoints following immune checkpoint blockade 
(60–62). Very recently, a study by Gao et al. demonstrated that the 
inhibitory immune checkpoint molecules PD-L1 and V-domain 
Ig suppressor of T cell activation are both upregulated in CD4+ 
and CD8+ T cells and CD68+ macrophages of prostate cancer 
patients in response to ipilimumab therapy (62). The upregulation 
of alternative checkpoints as a compensatory mechanism might 
explain the lack of response or partial tumor regression observed 
in preclinical models (60, 61) and in cancer patients when treated 
with anti-CTLA-4 or anti-PD-1 monotherapy (16, 62, 63).
Such compensatory mechanism by which the immune system 
strives toward balance is supported by increasing evidence, 
indicating that basic signaling mechanisms of several immune 
checkpoint pathways are intertwined with each other forming a 
complex network that regulates the immune response. Kamphorst 
et al. found that CD28 signaling is essential for T cells to effec-
tively respond to PD-1 blockade during chronic viral infection 
(64). Through conditional gene deletion, they showed a cell-
intrinsic requirement of CD28 for CD8 T cell proliferation after 
PD-1 therapy (64). Moreover, Hui et  al. reported that CD28 is 
strongly preferred over the TCR as a target for dephosphorylation 
by PD-1-recruited SHP-2 phosphatase, revealing that signaling 
through PD-1 occurs mainly by inactivating CD28 signaling (65). 
These data suggest that there is a broader interaction between 
PD-1 and CD28 than previously assumed, and such interaction 
might serve as a general mechanism for enhancing normal T cell 
responses and revitalizing exhausted T cells (66).
The unprecedented clinical success of cancer immunotherapy 
and the subsequent development of irAEs seen with these 
therapies have enabled researchers to study the underlying 
mechanisms of the early stages of autoimmunity. The expression 
of inhibitory receptors has been reported to be altered in many 
autoimmune diseases (67, 68), which suggests that signaling by 
inhibitory receptors is involved in the etiology of autoimmune 
diseases (67, 69). However, whether defective expression and/or 
function of immune checkpoints is a cause or consequence of 
autoimmunity and the ensuing autoimmune diseases is largely 
unknown. One factor that may be involved is age since aging is 
known to alter many aspects of the immune system and increases 
the susceptibility for the development of autoimmune diseases.
iMPAct OF AGiNG AND 
iMMUNOseNesceNce ON cHecKPOiNt 
MOlecUle eXPressiON
As a result of aging-related changes in the immune system, the 
human body becomes more susceptible for developing cancer, 
autoimmune diseases, infections, and cardiovascular diseases 
(70–73). Aging impacts both the innate and adaptive constituents 
of the immune system, which lead to a dysregulated immune and 
inflammatory response contributing to the increased incidence 
of chronic immune-mediated diseases in elderly individuals (74).
The immune system of aged people shows an accumulation 
in the frequency of highly differentiated T  cells of which, due 
to a greater homeostatic stability, CD4+ T  cells are being less 
affected by the age-associated phenotypic and functional changes 
than CD8+ T  cells (75, 76). These changes include loss of the 
cell surface costimulatory molecules CD27 and CD28, CD8+ 
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T  cells losing CD28 first followed by CD27 and vice  versa for 
CD4+ T cells (77). Loss of the costimulatory molecule CD28 is a 
hallmark of the age-related decline of T cell function, which has 
been associated with a less-efficient capability to mediate immune 
responses in old individuals (78).
In addition to the loss of costimulatory molecules, there is an 
increase in the expression of inhibitory receptors, which adds 
to T  cell dysfunction during aging (79). The expression of the 
inhibitory checkpoint molecule, CTLA-4 increases with age (80), 
whereas the expression of PD-1 is considered to be dependent on 
viral status rather than age and may also serve as a useful marker 
on viral-specific CD8+ T  cells to indicate the degree of T  cell 
exhaustion (41). In chronic viral infections and tumor microen-
vironments, PD-1-expressing exhausted cells lose their ability to 
produce IFN-γ and TNF-α and therefore become dysfunctional 
(81–83).
The age-related changes and deterioration of the immune 
system have been linked to immunosenescence (84), a term refer-
ring to the continuous remodeling of lymphoid organs, which 
leads to reduced immune function in elderly people (85). One 
of the major factors that fuels immunosenescence appears to be 
the lifelong chronic antigen load (86, 87) including leakage of 
microbial products from the gut to the circulation, resulting in 
continuous stimulation of both innate and adaptive immunity. 
Altogether, these changes lead to a chronic pro-inflammatory 
state favoring the development of age-associated (auto) inflam-
matory diseases (88).
rOle OF iMMUNe cHecKPOiNts iN tHe 
DevelOPMeNt OF iMMUNe-MeDiAteD 
vAscUlitis
Vasculitides are a heterogeneous group of inflammatory disor-
ders characterized by inflammation of the blood vessel wall. The 
clinical manifestations are determined by the localization, the 
type of vessel involved, and the nature of the inflammatory pro-
cess (89). The Chapel Hill nomenclature classifies non-infectious 
vasculitides mainly according to the type of vessel affected: LVV, 
medium vessel vasculitis (MVV), and small vessel vasculitis 
(SVV). LVV affects the aorta and its main branches, and the pri-
mary vasculitides in this group are GCA and Takayasu arteritis. 
MVV affects the main visceral arteries and its branches; examples 
of diseases in this group are polyarteritis nodosa and Kawasaki 
disease. Finally, SVV is further subdivided into antineutrophil 
cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and 
immune complex SVV. The major clinicopathologic variants of 
AAV are GPA, microscopic polyangiitis (MPA), and eosinophilic 
granulomatosis with polyangiitis (EGPA) (90).
Antineutrophil cytoplasmic antibody-associated vasculitis 
is predominantly disease of the elderly. The incidence of AAV 
increases with age, peaking in those aged 65–74 years (91–93). A 
hallmark of the AAV is the presence of autoantibodies directed 
at neutrophil cytoplasmic constituents (ANCA) (94, 95). The 
target antigens of ANCA in the AAV are proteinase 3 (PR3) 
and myeloperoxidase (MPO) where GPA is primarily associ-
ated with PR3-ANCA and MPA and EGPA with MPO-ANCA. 
The immunopathological model of AAV in the acute effector 
phase is centered around ANCA and pro-inflammatory stimuli, 
most likely of infectious origin, which synergize in initiating a 
destructive inflammatory process (94, 95). A central event in this 
process is ANCA-mediated neutrophil activation resulting in the 
generation of reactive oxygen species (ROS), degranulation and 
cytokine production, a process that is greatly facilitated by minor 
(pro-)inflammatory stimuli that prime the neutrophil to interact 
with ANCA. Upon disease progression, acute vasculitis lesion 
transform into lesions that predominantly contain macrophages 
and T cells.
Although data on checkpoint expression in AAV patients 
are scarce, Wilde et  al. reported increased expression of PD-1 
on circulating T helper cells of GPA patients, whereas T cells in 
renal lesions mostly lacked PD-1 (96). The authors found that 
PD-1 expression was positively correlated with expansion of 
memory T  cells, CD28null T  cells, as well as with T  cell activa-
tion. In addition, PD-1 expression was found to be enhanced on 
pro-inflammatory IFN-γ T cells in GPA patients. These observa-
tions suggested that increased PD-1 expression on T cells might 
counterbalance persistent T cell activation (96).
Furthermore, Slot et al. analyzed single-nucleotide polymor-
phisms in the genes encoding PD-1 and CTLA-4 describing SNP 
frequencies in GPA patients that could explain hyperreactivity 
of T cells in these patients (97). Interestingly, in 2016, our group 
reported for the first time the development of GPA after sequential 
immune checkpoint inhibition with anti-CTLA-4 and anti-PD-1 
treatment, as well as the first report of vasculitis observed after 
anti-PD-1 treatment (7). In that case report, we hypothesized that 
anti-CTLA-4 treatment induced PR3-ANCA production, which 
created the conditions necessary for the development of GPA, a 
process that was rapidly amplified by anti-PD-1 treatment (7).
GCA, the most common vasculitis after 50 years of age (98, 
99), is thought to be caused by both changes in the aging vessel 
wall and in the immune system. The immunopathological model 
of GCA can be divided into four phases: in phase 1, there is a 
loss of tolerance (cause unknown) and activation of resident DCs 
of the adventitia, which results in the recruitment, activation, 
and polarization of CD4+ T cells (phase 2). Once recruited and 
activated in the arterial wall, the presence of pro-inflammatory 
cytokines (e.g., IL-12, IL-18, IL-23, IL-6, and IL-1β) in the micro-
environment polarizes CD4+ T cells toward Th1 and Th17 cells. 
Th1 and Th17 are responsible for the production of large amounts 
of IFN-γ and IL-17, respectively, which ultimately leads to the 
recruitment of CD8+ T cells and monocytes (phase 3). Vascular 
remodeling (phase 4) starts when the IFN-γ-stimulated mono-
cytes differentiate into macrophages and vascular smooth muscle 
cells differentiate into myofibroblasts producing IL-6, IL-1β, 
TNF-α, and vascular endothelial growth factor (99). This ampli-
fies the local inflammatory response causing the release of toxic 
mediators for the arterial tissue such as ROS and matrix metal-
loproteinase, which eventually results in remodeling processes 
leading to intima proliferation and vascular occlusion (99, 100).
Accumulating evidence, including the case herein reported, 
points to an important role of immune checkpoints in the devel-
opment of GCA. This is also emphasized by the demonstrated 
efficacy of abatacept; a new treatment for GCA (99, 101). This 
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agent is a soluble fusion protein consisting of the ligand-binding 
domain of CTLA-4 and the Fc region derived from IgG1. CTLA-
4-Ig binds to the APC B7 (CD80/86) molecule, thereby blocking 
B7 interaction with the CD28/CTLA-4 receptor on the T  cell 
(102). By contrast, ipilimumab antagonizes the action of CTLA-4, 
thus enhancing immune reactivity by releasing this immunosup-
pressive checkpoint.
The involvement of immune checkpoints in the development 
of autoimmune side events is further supported by evidence from 
oncology, which shows that both CTLA-4 and PD-1 blockade 
result in enhanced Th17 cell responses and impaired Treg sur-
vival and function (52, 53, 56, 103). In addition, PD-1 blockade 
results in enhanced Th1 cell responses and increased production 
of cytokines such as IL-6 and IL-17 (103). This T cell functional 
flexibility and plasticity might be one of the mechanisms involved 
in the induction of autoimmune side effects (6).
In addition to CTLA-4 involvement in GCA, a recent study 
indicates that the immunoprotective PD-1/PD-L1 signaling 
pathway is affected as well. The study showed that tissue-residing 
DCs of GCA patients were low in PD-L1, whereas the majority 
of vasculitic T cells at the site of inflammation expressed PD-1 
(104). Moreover, the in  vivo vasculitogenic potential of PD-1 
blockade was demonstrated using a humanized mouse model 
system of vasculitis, the Human Artery-Severe Combined 
Immunodeficiency Mouse Chimera model. Briefly, human axil-
lary arteries were engrafted into NSG mice, and PBMCs from 
GCA patients or healthy individuals were adoptively transferred 
into the chimeras; chimeras were randomly assigned to treatment 
with PD-1 antibody or isotype control antibody. In this model, 
the authors confirmed that inhibiting PD-1/PD-L1 interaction 
enhanced tissue inflammation as GCA PBMCs but not healthy 
PBMCs were able to induce vasculitis. More specifically, PD-1 
blockade enabled very few healthy T cells to enter the vascular 
wall, while PBMCs from GCA patients induced vessel wall 
inflammation. These observations suggested that T  cells from 
GCA patients are especially vulnerable to PD-1 blockade (104, 
105).
Zhang et al. demonstrated that in GCA a breakdown in PD-1/
PD-L1 checkpoint resulted in unleashed vasculitic immunity and 
that such breakdown was responsible for the pathogenic remod-
eling of the inflamed arterial wall (104). The authors reported 
that PD-1 blockade gave rise to T cells producing IFN-γ, IL-17, 
and IL-21, which sustained multifunctional effector functions 
associated with the rapid outgrowth of hyperplastic intima and 
the induction of microvascular neoangiogenesis (104). Worthy of 
note, T cells producing IFN-γ, IL-17, and IL-21 play an important 
role in GCA and contribute to the pathogenesis of the disease 
(106, 107). Furthermore, PD-1 blockade biased T  cells toward 
increased T-bet and RORC expression and diminished FoxP3 
expression (104).
cONclUDiNG reMArKs
During the past decade, the introduction of ICIs has revolution-
ized cancer therapy and has proven to be a very effective strategy 
in inducing durable antitumor responses in multiple cancer types. 
Increasing evidence supports the idea that immune checkpoints 
cannot be regarded as separate pathways but as a complex 
network functioning in concert to maintain the delicate balance 
in the immune system. However, despite the clear therapeutic 
benefit, it is undeniable that the induction of irAEs is a serious 
disadvantage. It has become clear that data on safety of immune 
checkpoint therapies need further study in elderly individuals 
(85). It might be that the patient’s age is a relevant risk factor for 
irAEs (108) as the immune system of an elderly person is likely 
to demonstrate age-associated changes in checkpoint expression 
and function, which may be altered due to the chronic, low-
grade inflammation. These changes imply that elderly patients 
will respond differently to ICI therapy than do younger patients 
evaluated in clinical trials.
Collectively, age-related changes and alterations in signaling 
pathways are complex and interconnected. These changes are 
likely to influence DC, Teff, and Treg pathways, increasing the 
likelihood of T cell suppression in the elderly (79). Indeed more 
research is needed to understand the link between age-related cel-
lular and molecular changes and their potential influence on DC 
and T cell pathways leading to the development of autoimmunity. 
Nonetheless, lessons learned from the oncology field are valuable, 
enabling researchers to realize that the immune system is capable 
of reconfiguring the immune checkpoint complex network after 
modulation using ICIs. The altered expression of inhibitory recep-
tors as seen in vasculitis patients, such as the abnormalities in the 
PD-1/PD-L1 pathway (105), hints at the involvement of immune 
checkpoints in disease development. Perhaps the use of agonistic 
inhibitory checkpoint molecules to halt self-damaging responses 
could restore the checks and balances, which are reported to be 
deficient in vasculitis.
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